Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HMPL-A580 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| HMPL-A580 | DRUG | Part A(Phase I) Dose Escalation Enrolled participants will receive HMPL-A580 treatment in a dose escalation setting initially at 6 predefined dose levels. |
HMPL-A580 is an investigational small molecule being developed for the treatment of solid tumors in adults. It is currently in clinical development for advanced or metastatic solid tumors, with an ongoing Phase 1/2a study evaluating its safety and efficacy in this patient population.
HMPL-A580 is being developed by HUTCHMED (China) Limited, a biopharmaceutical company listed on the stock exchange under the ticker HCM. The company is conducting clinical trials to evaluate the drug's potential in treating solid tumors.
HMPL-A580 is in Phase 2 clinical development, specifically in a Phase 1/2a study. The trial is designed to assess the drug in participants with advanced or metastatic solid tumors. As an investigational agent, it has not yet been approved by regulatory authorities.
HMPL-A580 is being studied in a single clinical trial with the identifier NCT07396584. This is a Phase 1/2a study in participants with advanced or metastatic solid tumors, with an estimated enrollment of 186 participants. The trial is not yet recruiting participants.
Yes, HMPL-A580 is a small molecule therapeutic. It is being developed as an oncology treatment for solid tumors in adults. The drug is currently in early-stage clinical development, with an ongoing Phase 1/2a trial assessing its use in advanced or metastatic solid tumors.